Camrelizumab Utilization on Patients With Advanced Liver Cancer

  • End date
    Jan 13, 2025
  • participants needed
  • sponsor
    First Affiliated Hospital Xi'an Jiaotong University
Updated on 13 May 2022


To observe and evaluate the safety and efficacy of camrelizumab in advanced liver cancer


camrelizumab , a humanized monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1, thereby inhibiting the immune escape of tumor cells. It has a high affinity for PD-1 (KD = 3.31 nmol/L), a high acceptor proportion (85% at 200 mg) of circulating T lymphocytes, and binds to epitopes different from Nivolumab and pembrolizumab,Phase 1 clinical trials have shown that camrelizumab is well tolerated and has antitumor activity in patients with advanced solid tumors.camrelizumab has been approved for indication for advanced hepatocellular carcinoma The main objective of this study was to observe and evaluate the safety and efficacy of treatment regiments containing Camrelizumab in advanced liver cancer。 The subjects included people over 18 years old, For men and women with advanced liver cancer confirmed by histopathology or cytology;

Condition Advanced Hepatocellular Carcinoma
Treatment Camrelizumab
Clinical Study IdentifierNCT04487704
SponsorFirst Affiliated Hospital Xi'an Jiaotong University
Last Modified on13 May 2022


Yes No Not Sure

Inclusion Criteria

years old or more
For both men and women
Patients with advanced liver cancer confirmed by histopathology or cytology; .Volunteer to join the study, sign the informed consent, good compliance, and cooperate with the follow-up

Exclusion Criteria

A known allergy to the study drug or any of its excipients; Or had a severe allergic reaction to other monoclonal antibodies
Patients who are ready for or have previously received an organ or allogeneic bone marrow transplant
Pregnant or lactating women
According to the judgment of the researcher, the patients should not be included in this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note